Clay B. Siegall

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Bothell, WA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Sandra Stoneman, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Clay B. Siegall

Form 4 holding President & CEO, Director

Seagen Inc.

Security class
Common Stock
Shares / value
666,060
Estimated value
$152,527,740
Report date
12 May 2022
Price
$229.00
Ownership
Direct
Form 4 holding President and CEO, Director

Immunome Inc.

Security class
Common Stock
Shares / value
870,704
Estimated value
$18,450,217
Report date
23 Jul 2026
Price
$21.19
Ownership
Direct
Form 4 holding President and CEO, Director

Immunome Inc.

Security class
Employee Stock Option (right to buy)
Shares / value
360,000
Estimated value
Report date
23 Jul 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Shattuck Labs, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
81,000
Estimated value
Report date
29 May 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President & CEO, Director

Seagen Inc.

Security class
Non-Qualified Stock Option (right to buy)
Shares / value
51,129
Estimated value
Report date
12 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Nurix Therapeutics, Inc.

Security class
Director Stock Option (right to buy)
Shares / value
17,500
Estimated value
Report date
05 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Tourmaline Bio, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
16,800
Estimated value
Report date
04 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Shattuck Labs, Inc.

Security class
Warrants (Right to Buy)
Shares / value
0
Estimated value
Report date
22 May 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Tourmaline Bio, Inc.

Security class
Employee Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
28 Oct 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Clay B. Siegall

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .